Cargando…

Evaluation of Latent Membrane Protein 1 as a novel vaccine adjuvant

Detalles Bibliográficos
Autores principales:	Termini, JM, Gupta, S, Stone, GW
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441903/ http://dx.doi.org/10.1186/1742-4690-9-S2-P11

Ejemplares similares

Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines
por: Gupta, Sachin, et al.
Publicado: (2011)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
por: Liu, J, et al.
Publicado: (2009)

Control of HIV replication by a novel constitutively active ‘super-PRR’
por: Gupta, S, et al.
Publicado: (2012)

CYPA, a novel and potential genetic adjuvant enhanced HIV-1 DNA vaccine immunoreactivity
por: Hou, J, et al.
Publicado: (2012)

Adjuvant-dependent cytokine profiles in the context of a DNA prime-protein boost HIV-1 vaccine
por: Buglione-Corbett, R, et al.
Publicado: (2012)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
por: Sabado, Rachel L, et al.
Publicado: (2013)

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 gag
por: Qiu, Jian-Tai, et al.
Publicado: (2006)

L-tyrosine is a promising cancer vaccine adjuvant
por: Khong, Hiep, et al.
Publicado: (2015)

Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion
por: Termini, James M., et al.
Publicado: (2017)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines
por: Blasi, M, et al.
Publicado: (2012)

Chromatin control of Tat-mediated reactivation of latent HIV-1 provirus
por: Masse, Guillemette X, et al.
Publicado: (2009)

Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
por: Berry, John S, et al.
Publicado: (2013)

Adjuvant radiotherapy after surgery in breast cancer: evaluation of acute toxicity
por: Molinaro, MA, et al.
Publicado: (2005)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Evaluation of effectiveness of protein expression of DNA vaccine in CHO Cells
por: Brum, Alexandre, et al.
Publicado: (2014)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

Identification and characterization of two novel centriolar appendage component proteins
por: Schrøder, JM, et al.
Publicado: (2012)

In vitro evaluation of HMGB1 removal with various membranes for continuous hemofiltration
por: Yumoto, M, et al.
Publicado: (2011)

Improving potency of Chlamydia trachomatis major outer membrane protein muli-epitope DNA vaccine by fusion with human papillomavirues 6b L1
por: Xu, Wen, et al.
Publicado: (2011)

P19-24. Evaluation of recombinant influenza-SIV vaccines in macaques
por: Stambas, J, et al.
Publicado: (2009)

Risk of latent tuberculosis in at-risk children with rheumatic diseases
por: Lim, SC, et al.
Publicado: (2011)

Analysis of Plasmodium falciparum erythrocyte membrane protein 1- DBLα domain variants with respect to antigenic variations and docking interaction analysis with glycosaminoglycans
por: Deobagkar, Deepti, et al.
Publicado: (2014)

Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
por: Greene, Julia, et al.
Publicado: (2014)

Identification and characterization of novel B-cell epitopes within EBV latent membrane protein 2 (LMP2)
por: Xue, Xiangyang, et al.
Publicado: (2011)

Identification and functional analysis of novel centrosomal proteins to study their implication in human disease
por: Jakobsen, L, et al.
Publicado: (2012)

P16-36. Functional genomic immune profile of SIV DNA vaccines delivered by electroporation and combined with molecular adjuvants
por: Boyer, JD, et al.
Publicado: (2009)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

Functional characterization of HIV-1 Nef proteins with heterologous membrane targeting signals
por: Geist, Miriam M, et al.
Publicado: (2013)

Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Membrane-associated RING-CH (MARCH) 8 protein inhibits HIV-1 infection
por: Koyama, Takayoshi, et al.
Publicado: (2013)

P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants
por: Cristillo, AD, et al.
Publicado: (2009)

Estimation of the latent therapeutic demand for albumin in the USA: a focus on three indications
por: Farrugia, A, et al.
Publicado: (2015)

Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
por: Antonios, Joseph, et al.
Publicado: (2015)

Sustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

RNAdjuvant(®), a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
por: Heidenreich, Regina, et al.
Publicado: (2015)

Protein structure prediction for novel mutations in Arylsulfatase-A gene
por: Divya, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_on1rm0c07n1oot8s0jqmf2orf9